To the Editor, We read with interest the NRG Oncology GOG-0263 Phase III clinical trial1, which compared adjuvant radiotherapy (RT) with chemoradiotherapy (CRT) in women with intermediate-risk, early-stage cervical cancer. While CRT significantly improved relapse-free survival (RFS), it conferred no overall survival (OS) benefit and markedly increased toxicity. Paradoxically, despite statistical significance, these findings raise concerns about their clinical relevance and applicability. This study complies with the TITAN 2025 guidelines for transparent and ethical reporting of AI-assisted research2. First, the trial does not report essential treatment parameters such as adherence, dose intensity, or early discontinuation. This omission is particularly problematic given the elevated toxicity observed in the CRT arm. Without these data, the comparative efficacy of CRT may be overestimated due to unmeasured performance bias. Additionally, the recurrence endpoint is inadequately defined: the lack of distinction between local, regional, and distant failures undermines RFS consistency, especially in a multicenter setting3. Second, risk stratification in this trial relies exclusively on legacy histopathologic features – tumor size, lymphovascular space invasion, and stromal invasion depth. This static, 20th-century framework does not reflect contemporary advances in biomarker-guided oncology. In the absence of post-operative circulating HPV DNA or minimal residual disease (MRD) surveillance, patients with negligible residual risk may be unnecessarily overtreated with CRT, while others with molecularly high-risk profiles may remain undertreated4. Pathology alone is insufficient for tailoring adjuvant intensity in the modern era. This exposes a critical gap between histologic surrogates and true residual disease burden – one that modern biomarkers and MRD assays are uniquely positioned to bridge. Third, the absolute RFS gain must be interpreted within a broader therapeutic value framework. The notable increase in severe toxicities – without OS improvement – raises questions about net clinical benefit. Yet the study omits patient-reported outcomes and omits integrative metrics such as quality-adjusted time without symptoms or toxicity (Q-TWiST)5. Without these, it is difficult to contextualize whether the survival benefit meaningfully offsets treatment burden in a curative setting. Collectively, this trial exemplifies a broader inertia in gynecologic oncology: continued reliance on static pathology-based decision-making, neglect of emerging molecular risk tools, and limited incorporation of patient-centered endpoints. As precision oncology becomes the standard, adjuvant therapy intensity must reflect not only recurrence risk but also patient tolerability, molecular biology, and long-term survivorship metrics6. In summary, while Takekuma et al provide valuable data on CRT efficacy in intermediate-risk cervical cancer, the absence of biological integration and patient-centered metrics limits translational relevance and risks entrenching outdated treatment paradigms. In an era demanding precision, adjuvant strategies must be guided by molecular risk profiling, dynamic MRD monitoring, and holistic benefit-risk frameworks. Treatment escalation should reflect true residual disease burden, minimize overtreatment, and align with outcomes that matter most to patients. This correspondence aims to inform future adjuvant protocols and clinical guidelines by highlighting key translational gaps and advocating for a shift toward biologically grounded, patient-informed decision-making in gynecologic oncology.
Sun et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: